Can-Fite Reports 2022 Financial Results & Provides Clinical

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory

Related Keywords

United States , Russia , Israel , Ukraine , Romania , American , Russian , Pnina Fishman , Motti Farbstein , Fite Biopharma , Kiryat Matalon , Soroka Medical Center , Trademark Office Granted Can , Exchange Commission , Clinical Development Highlights , Company Annual Report On Form , Fite Biopharma Ltd , European Medicines Agency , Drug Administration , Can Fite Biopharma , Clinical Development Highlights Include , Trial Met Primary Endpoint , Psoriasis Area , Severity Index , Registration Plan , Piclidenoson Submitted , Topical Psoriasis Treatment , Significantly Inhibit Pancreatic Cancer , Preclinical Studies , Trademark Office Granted Can Fite , Liver Fibrosis , Treating Fibrotic Liver Tissue Using , Advanced Clinical Studies , Cancer Study , Complete Response , Advanced Liver Cancer Treated , Compassionate Use , Decompensated Liver Cirrhosis Will Be Treated , Namodenoson Under Compassionate Use , Annual Report , Can Fite Investor Relations , Orphan Drug Designation , Fast Track Designation , Ifite , Reports , 022 , Financial , Results , Rovides , Linical , Update ,